SCHEMBL2385379

SCHEMBL2385379

CCc1ccc(F)c(NC(=O)N2CCN(c3nsnc3OCc3ccnc(N)n3)CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.38
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
PI4KB Q9UBF8 2/20 0.36
PDGFRB P09619 1/20 0.36
P2RY12 Q9H244 5/20 0.36
PKM P14618 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
KIT P10721 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
RBP4 P02753 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384688 0.90 MAPK1 (0.46) TRPV1MAPK1NPSR1ALDH1A1MAPT
SCHEMBL2386446 0.90 ALDH1A1 (0.38) TRPV1MAPK1NPSR1ALDH1A1MAPT
SCHEMBL2384209 0.88 TRPV1 (0.40) TRPV1MAPK1NPSR1PDGFRBKIT
SCHEMBL2384857 0.87 MEN1 (0.43) TRPV1MAPK1NPSR1ALDH1A1MAPT
SCHEMBL2385328 0.87 P2RY12 (0.42) TRPV1NPSR1ALDH1A1MAPTPI4KB
SCHEMBL2384924 0.87 PI4KB (0.44) MAPTPI4KBPDGFRBP2RY12KMT2A
SCHEMBL2381557 0.86 MAPT (0.41) ALDH1A1MAPTPI4KBPDGFRBP2RY12
SCHEMBL2384914 0.85 P2RY12 (0.46) TRPV1NPSR1ALDH1A1MAPTPI4KB
SCHEMBL12302910 0.85 PDGFRB (0.38) ALDH1A1MAPTPI4KBPDGFRBP2RY12
SCHEMBL2383928 0.85 MEN1 (0.42) TRPV1MAPK1MAPTPDGFRBP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR TRPV1 4108/4885MAPK1 263/4885NPSR1 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.